Nurix Enrolled First Patient in Bexobrutideg Trial
The Phase 1b/2 clinical study evaluates a combination therapy for chronic lymphocytic leukemia patients.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies should prioritize developing combination drug therapies for cancer treatment?
Nurix Therapeutics has enrolled the first patient in a Phase 1b/2 clinical trial assessing the drug bexobrutideg in combination with venetoclax. This study investigates the safety and efficacy of the treatment for individuals suffering from chronic lymphocytic leukemia.
Why it matters
Combination therapies have become a central focus in modern oncology to improve treatment outcomes for chronic lymphocytic leukemia patients. This trial aims to determine if pairing this degrader with a standard BCL2 inhibitor offers better results than current protocols.
The study tests bexobrutideg, an oral Bruton's tyrosine kinase degrader, alongside venetoclax, an established BCL2 inhibitor. Researchers are analyzing the safety, tolerability, and clinical activity of this combination during the Phase 1b/2 stage.
The players
Nurix Therapeutics
A California-based biopharmaceutical company focused on the discovery and development of novel therapies that modulate cellular protein levels.
Roche
A global healthcare leader and pharmaceutical giant that is collaborating with Nurix on the global clinical development of the combination therapy.
The details
The trial is conducted under a global partnership between Nurix Therapeutics and Roche. Researchers plan to use data from this study to inform future development strategies, with potential expansions into first-line treatments and other B-cell malignancies.
Timeline
October 6, 2026: The first patient was enrolled in the Phase 1b/2 study.
The Tech Race
This trial marks an important milestone in the development of targeted protein degraders, a technology designed to outperform traditional inhibitors. It positions Nurix and Roche within a competitive field striving to replace legacy cancer treatment systems with more precise biological interventions.
While the trial is currently in an early phase, successful outcomes could eventually lead to new, more effective treatment standards for leukemia patients. Participants gain access to experimental therapies that combine established BCL2 inhibitors with novel protein degradation science.
The takeaway
This study represents a significant move toward integrating protein degradation technology into standard oncology workflows. The results will ultimately determine if this dual-drug approach provides a viable path forward for expanding treatment options in B-cell malignancies.
Further reading
Learn more about the latest innovations in pharmaceutical research on our Biotech page.
More information
For official information regarding ongoing research, visit the clinical trials information lookup.
Live Poll
Do you believe pharmaceutical companies should prioritize developing combination drug therapies for cancer treatment?
